A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Background The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or
angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and …

Diabetic nephropathy is manifested in more than 10% of people with diabetes. It is a
common cause of kidney failure and end-stage kidney disease. Understanding of …

Chronic kidney disease (CKD) is inherently an inflammatory condition, which ultimately
results in the development of end stage renal disease or cardiovascular events. Low-grade …

Impaired cellular cholesterol efflux is a key factor in the progression of renal, cardiovascular,
and autoimmune diseases. Here we describe a class of 5-arylnicotinamide compounds …

Chronic kidney disease (CKD) is a comorbidity of major clinical significance amongst people
living with HIV (PLWHIV) and is associated with significant morbidity and mortality. The …

Chronic kidney disease (CKD) is a severe clinical syndrome with significant socioeconomic
impact worldwide. Orderly energy metabolism is essential for normal kidney function and …

Diabetic nephropathy (DN) is regarded as the leading cause of end-stage renal disease
worldwide and lacks novel therapeutic targets. To screen and verify special biomarkers for …

Aim To quantify the impact of foot complications on mortality outcomes in people with type 2
diabetes (T2D), and how routinely measured factors might modulate that risk. Materials and …

Background: Although angiotensin-converting enzyme (ACE) inhibitors are among the most-
prescribed medications in the world, the extent to which they increase the risk of adverse …